This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutStudy Design1L study design2L+ study designEfficacy1L overall efficacy1L CNS efficacy1L 36-month overall efficacy1L 36-month CNS efficacy2L+ efficacySafetyPooled Safety: all lines1L safety2L+ safetyDosing & Therapy ManagementDosingTherapy management

The information on this website is based on data from adult patients with ALK-positive advanced NSCLC (anaplastic lymphoma kinase positive advanced non small cell lung cancer) treated with LORVIQUA▼(lorlatinib), produced in line with the LORVIQUA (lorlatinib) Summary of Product Characteristics.
LORVIQUA (lorlatinib) Prescribing Information click here.
▼LORVIQUA is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. Adverse event reporting information can also be found at the bottom of the page.

Generally manageable safety profile with largely mild-to-moderate adverse reactions1

Data described here are reflective of the CROWN trial, a Phase 3 study of LORVIQUA vs crizotinib in patients with previously untreated, ALK-positive, locally advanced or metastatic NSCLC.1 

The most common adverse reactions are reported below.

ARs (any grade) occurring in ≥10% of patients treated with LORVIQUA (N=149)1,a
Scroll left to view table
Adverse reaction Any grade Grades 3 and 4
Hypercholesterolaemiab 70.5% 16.1%
Hypertriglyceridaemiab 63.8% 20.1%
Oedemab 55.0% 4.0%
Weight increased 38.3% 16.8%
Peripheral neuropathyb 33.6% 2.0%
Cognitive effectsb,c 21.5% 2.0%
Diarrhoea 21.5% 1.3%
Anemia 19.5% 2.7%
Fatigueb 19.5% 1.3%
Hypertension 18.1% 10.1%
Vision disorderb 18.1% 0.0%
Increased ALT level 17.4% 2.7%
Constipation 17.4% 0.0%
Mood effectsb,d 16.1% 1.3%
Nausea 14.8% 0.7%
Increased AST level 14.1% 2.0%
Vomiting 12.8% 0.7%
Hyperlipidemia 10.7% 2.0%
Adapted from Shaw AT, et al. N Engl J Med. 2020.
  • In the CROWN study, permanent discontinuations and dose reductions associated with adverse reactions occurred in 7.0% and 21.0% of patients with LORVIQUA and 9.0% and 15.0% with crizotinib, respectively1,a 
  • 35.0% of patients receiving LORVIQUA in the CROWN study reported CNS adverse events, but by time of analysis 56.0% had resolved and most required no intervention (33.0% resolved without intervention, 17.0% with dose modification)2,a 
  • Adverse reactions can be effectively managed with dose modifications and/or standard supportive medical therapy, without affecting the efficacy of LORVIQUA2,3 

Learn more about therapy management

ALT=alanine aminotransferase; AST=aspartate aminotransferase; AR=adverse reaction.aBased on data from 18-month median follow-up of 149 patients who received LORVIQUA 100 mg once daily in the Phase 3 CROWN trial.1bThis category comprised a cluster of adverse events that may represent similar clinical symptoms or syndromes. cCognitive effects with a frequency of at least 1% included memory impairment, disturbance in attention, confusion, amnesia, cognitive disorder, and delirium.dMood effects with a frequency of at least 1% included anxiety, depression, affect lability, affective disorder, agitation, irritability, and altered mood.References:Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.Solomon BJ, Bauer TM, Ou SHI, et al. Post hoc analysis of lorlatinib efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the Phase III CROWN study. J Clin Oncol. Published online May 23, 2022. doi: 10.1200/JCO.21.02278.Bauer TM, Felip E, Solomon BJ, et al. Clinical management of adverse events associated with lorlatinib. Oncologist. 2019;24(8):1103-1110.Safety
Therapy management
 See the strategies  Loading
LORVIQUA efficacy
 Discover the data Loading
PP-LOR-IRL-0074 February 2024 Legal Category S1A Further information available on request

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0784. June 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0784. June 2024